PharmiNews

The Directory of Pharma Companies and News

Janssen

Janssen logo
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world. The legal entity for Janssen in the UK and Ireland is Janssen-Cilag Ltd.
Category: Pharmaco
Category: Pharmaco

Janssen News

DateNews
2015-09-15Janssen Initiates FIRST, a Novel Study to Evaluate the Benefit of Caregiver Education in Improvement of Outcomes for Pat... (PDF)
2015-09-01New Global Real-World Data from Atrial Fibrillation Studies Confirm the Safety Profile of XARELTO® (PDF)
2015-06-25INVEGA TRINZA™, First and Only Four-Times-A-Year Treatment for Schizophrenia, Now Commercially Available (PDF)
2015-05-19U.S. FDA Approves INVEGA TRINZA™, First and Only Four-Times-A-Year Treatment for Schizophrenia (PDF)
2015-05-19Real-World Data Presented at American Geriatrics Society Meeting Show Consistent Safety of XARELTO® in Elderly Patients (PDF)
2015-05-14New Data on XARELTO® Versus Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing Catheter Ablation Presented... (PDF)
2015-05-11U.S. FDA Issues Complete Response Letter to sNDA Seeking to Expand the Label for INVEGA SUSTENNA® (PDF)
2015-04-15Study Published in The Journal of Clinical Psychiatry Shows INVEGA SUSTENNA® Effective Six Months Longer Than Common Ora... (PDF)
2015-03-30New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO® Compared t... (PDF)
2015-03-02Findings to be Presented at Annual Scientific Session of the American College of Cardiology (ACC) About an Additional Po... (PDF)
2015-01-19FDA Grants Priority Review for Three-Month Paliperidone Palmitate for the Treatment of Schizophrenia (PDF)
2015-01-14Real-World Data Published in Clinical Cardiology Show Consistent Safety Performance of Once-Daily XARELTO® (PDF)
2014-12-09Janssen Teaming Up to Take On Diabetes (PDF)
2014-11-13U.S. FDA Approves Supplemental New Drug Applications for Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidon... (PDF)
2014-10-21Janssen Pharmaceuticals and Diabetes Hands Foundation Encourage People with Type 2 Diabetes to Get Moving for National D... (PDF)
2014-09-25Study Observed Association between JANSSEN® CONNECT® Injection Centers and Increased Adherence to Healthcare Provider-Or... (PDF)
2014-08-08U.S. FDA Approves INVOKAMET™ (canagliflozin/metformin HCl) for the Treatment of Adults with Type 2 Diabetes (PDF)
2014-07-14Janssen Pharmaceuticals Seeks Expanded Label for Once-Monthly INVEGA® SUSTENNA® (paliperidone palmitate) to Show Delayed... (PDF)
2014-05-13Supplemental New Drug Applications for Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidone palmitate) Submi... (PDF)
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.